PT861073E - Preparacoes de hormona da tiroide estabilizadas e metodos para prepara-las - Google Patents

Preparacoes de hormona da tiroide estabilizadas e metodos para prepara-las

Info

Publication number
PT861073E
PT861073E PT96938414T PT96938414T PT861073E PT 861073 E PT861073 E PT 861073E PT 96938414 T PT96938414 T PT 96938414T PT 96938414 T PT96938414 T PT 96938414T PT 861073 E PT861073 E PT 861073E
Authority
PT
Portugal
Prior art keywords
preparations
disclosed
thyroid hormone
preparing
methods
Prior art date
Application number
PT96938414T
Other languages
English (en)
Portuguese (pt)
Inventor
K Mitra Amit
Raghunath Srinivas
Charles L Thomas Iii
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of PT861073E publication Critical patent/PT861073E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT96938414T 1995-11-14 1996-11-14 Preparacoes de hormona da tiroide estabilizadas e metodos para prepara-las PT861073E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US673895P 1995-11-14 1995-11-14
US1731496P 1996-05-13 1996-05-13

Publications (1)

Publication Number Publication Date
PT861073E true PT861073E (pt) 2004-10-29

Family

ID=26675995

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96938414T PT861073E (pt) 1995-11-14 1996-11-14 Preparacoes de hormona da tiroide estabilizadas e metodos para prepara-las

Country Status (12)

Country Link
US (2) US5955105A (OSRAM)
EP (1) EP0861073B1 (OSRAM)
JP (1) JP2000500155A (OSRAM)
AT (1) ATE271863T1 (OSRAM)
AU (1) AU712217B2 (OSRAM)
BR (1) BR9611306A (OSRAM)
CA (1) CA2235707A1 (OSRAM)
DE (1) DE69633018T2 (OSRAM)
ES (1) ES2224184T3 (OSRAM)
MX (1) MXPA98003802A (OSRAM)
PT (1) PT861073E (OSRAM)
WO (1) WO1997017951A1 (OSRAM)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
DE19830246A1 (de) 1998-07-07 2000-01-13 Merck Patent Gmbh Pharmazeutische Zubereitung
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
JP2002540073A (ja) * 1999-03-10 2002-11-26 ロータス バイオケミカル コーポレイション 化学化合物の保護および放出のためのタンパク質コンホメーションの使用
WO2001015665A1 (en) * 1999-09-02 2001-03-08 Nostrum Pharmaceuticals, Inc. Controlled release oral dosage suitable for oral administration
US6627660B1 (en) 1999-11-16 2003-09-30 New River Pharmaceuticals Inc. Stabilized thyroxine compounds
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US6399101B1 (en) * 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
JP4902928B2 (ja) 2000-05-24 2012-03-21 大塚製薬株式会社 製剤の安定化方法
EP1157682A1 (en) * 2000-05-25 2001-11-28 Cilag AG Blister package for topiramate tablets
US6979462B1 (en) 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6855333B1 (en) 2000-10-03 2005-02-15 Mutual Pharmaceutical Co., Inc. Stabilization of solid thyroid drug formulations
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
SK288217B6 (sk) 2001-01-26 2014-08-05 Merck Sharp & Dohme Corp. Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie
BRPI0206641B8 (pt) 2001-01-26 2021-05-25 Merck Sharp & Dohme uso de um inibidor da absorção de esteróis
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
ITMI20011401A1 (it) * 2001-07-02 2003-01-02 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei
AU2002332507A1 (en) * 2001-08-10 2003-02-24 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030194436A1 (en) * 2001-08-10 2003-10-16 Franz Andrew G. Immediate release pharmaceutical compositions
US20030199585A1 (en) * 2001-08-10 2003-10-23 Franz G Andrew Levothyroxine compositions and methods
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
WO2003028624A2 (en) * 2001-08-14 2003-04-10 King Pharmaceuticals, Inc Levothyroxine compositions and methods
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US7101569B2 (en) * 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030194437A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Cmax properties
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
DE60216300T2 (de) 2001-09-21 2007-06-28 Schering Corp. Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US20030190350A1 (en) * 2001-10-29 2003-10-09 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
PL369972A1 (en) * 2002-01-07 2005-05-02 Abbott Gmbh & Co.Kg Crystallization of amino acids using ultrasonic agitation
WO2003099214A2 (en) * 2002-05-23 2003-12-04 Andrx Corporation Biguanide formulations
WO2004014318A2 (en) * 2002-08-10 2004-02-19 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
WO2004041208A2 (en) * 2002-11-05 2004-05-21 New River Pharmaceuticals Inc. Controlled absorption of mixed thyroyd hormone formulations
AU2003291719A1 (en) 2002-11-06 2004-06-03 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
CA2517573C (en) * 2003-03-07 2011-12-06 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CN1756756A (zh) * 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
PT1622587E (pt) * 2003-05-02 2010-07-07 Globopharm Pharmazeutische Pro Preparaã†o farmac—utica sëlida contendo sais de levotiroxina e/ou liotironina
US8293272B2 (en) * 2003-05-02 2012-10-23 Globopharm Pharmazeutische Produktions-Und Handelsgesellschaft M.B.H. Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
GB0316206D0 (en) * 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation
US20060008512A1 (en) * 2004-07-07 2006-01-12 Hooge Danny M Composition and methods for improved animal performance
US8318712B2 (en) * 2006-01-06 2012-11-27 Intervet International B.V. Concentrated liquid thyroid hormone composition
US7858663B1 (en) 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
GB2457710A (en) * 2008-02-25 2009-08-26 Andrew Nicolaou Thyroxine and its use in weight loss and obesity treatment
IT1395454B1 (it) * 2009-03-24 2012-09-21 Altergon Sa Composizioni e forme farmaceutiche per somministrazione orale di ormoni tiroidei in grado di contrastare l'azione di agenti sequestranti nel tratto gastrointestinale
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
CA2805958A1 (en) * 2009-08-04 2011-02-10 Haren Treasurer Greater utility with thyroid hormone
EP2627318B1 (en) 2010-10-12 2017-08-16 Merz Pharma GmbH & Co. KGaA Formulation suitable for stabilizing proteins, which is free of mammalian excipients
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
EP3260443B1 (en) * 2011-04-08 2020-10-07 Bracco Imaging SPA A pharmaceutical composition comprising a sulfated derivative of 3,5-diiodo-o-[3-iodophenyl]-l-tyrosine
US9006289B2 (en) * 2011-08-30 2015-04-14 Fresenius Kabi Usa, Llc Levothyroxine formulations
US8779000B1 (en) * 2013-07-20 2014-07-15 Nilesh Parikh Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production
EP2932963A1 (en) * 2014-04-16 2015-10-21 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable pharmaceutical dosage forms comprising Levothyroxine sodium
WO2017013591A1 (en) 2015-07-22 2017-01-26 Leiutis Pharmaceuticals Pvt Ltd Stabilized liquid formulation of levothyroxine
DE112016005058T5 (de) 2015-11-04 2018-07-19 Leiutis Pharmaceuticals Pvt Ltd Neue Levothyroxin-Formulierungen zur oralen Anwendung
NL2017110B1 (en) * 2016-07-05 2018-01-12 Emp Levo Gmbh Methods for the preparation of a levothyroxine solution
US10231931B1 (en) 2018-03-23 2019-03-19 Genus Lifesciences Inc. Thyroid hormone oral dosage forms and methods of using the same
TW202227047A (zh) * 2020-10-09 2022-07-16 日商Ａｓｋａ製藥股份有限公司 甲狀腺荷爾蒙的製劑化方法
WO2023088976A1 (en) 2021-11-16 2023-05-25 Tap Pharmaceuticals, Ag Orodispersible levothyroxine compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5275820A (en) * 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5225204A (en) * 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
EP0550108B1 (en) * 1991-12-30 1998-03-18 Akzo Nobel N.V. Sustained release thyroactive composition
DE4318577A1 (de) * 1993-06-04 1994-12-08 Merck Patent Gmbh Schmiermittelfreie, arzneimittelhaltige Tabletten
GB9401879D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
GB9401892D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
HUT75956A (en) * 1995-11-29 1997-05-28 Cyclolab Pharmaceutical composition containing thyroxine

Also Published As

Publication number Publication date
EP0861073B1 (en) 2004-07-28
DE69633018D1 (de) 2004-09-02
ES2224184T3 (es) 2005-03-01
BR9611306A (pt) 1999-12-28
WO1997017951A1 (en) 1997-05-22
DE69633018T2 (de) 2004-12-09
AU712217B2 (en) 1999-11-04
EP0861073A1 (en) 1998-09-02
AU7584996A (en) 1997-06-05
JP2000500155A (ja) 2000-01-11
MXPA98003802A (es) 2005-04-29
US5955105A (en) 1999-09-21
US6056975A (en) 2000-05-02
CA2235707A1 (en) 1997-05-22
ATE271863T1 (de) 2004-08-15

Similar Documents

Publication Publication Date Title
PT861073E (pt) Preparacoes de hormona da tiroide estabilizadas e metodos para prepara-las
DE68904121D1 (de) Ibuprofen-cyclodextrin-einschlusskomplexe enthaltende pharmazeutische zubereitungen.
KR890004686A (ko) 서방성 에토돌락
CA2033725A1 (en) Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
EP0787497A3 (en) Pharmaceutical preparation containing human growth hormone
DE3787061D1 (de) Chelatierte aminosaeurezusammensetzungen zur verabreichung an bestimmte gewebestellen.
BG101781A (bg) Твърд препарат, съдържащ активно вещество
IE882671L (en) Stabilised human protein formulation
NZ215350A (en) #q#-cyclodextrin ethers and pharmaceutical compositions
AU678344B2 (en) Lipophilic oligosaccharide antibiotic salt compositions
BR9812835A (pt) Composição de gel para barbear não-aerossol
KR900014406A (ko) 세펨 화합물 및 이의 제조방법
FR2380782A1 (fr) Fraction 5 de thymosine stabilisee utile comme medicament et procede pour la preparer
AU566228B2 (en) Compressed hydroxybutryic acid polymer retarded release vehicle
TW372193B (en) Novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredient
JPS6416724A (en) Stable and injectable vinca dimer salt solution
AU8595791A (en) Galactomannan derivatives for coating or embedding medicinally active substances
FR2794976B1 (fr) Compositions pharmaceutiques a action cicatrisante ou anti-complementaire comprenant un derive de dextrane
EP0397147A3 (en) Stable solutions of rebeccamycin analog and preparation thereof
AU6922891A (en) Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol
PT1058544E (pt) Inibicao da actividade do tnf
JPS6416728A (en) Aqueous preparation
GB2258397A (en) Pharmaceutical compositions containing amethocaine
JPS57200361A (en) "indomethacin(r)" pharmaceutical with low irritant action
KR900015732A (ko) 경구용 제제